Effects of Belimumab combined with Hydroxychloroquine and Prednisone in treatment of patients with systemic lupus erythematosus
Objective:To observe effects of Belimumab combined with Hydroxychloroquine and Prednisone in treatment of patients with systemic lupus erythematosus.Methods:A prospective study was conducted on 90 patients with systemic lupus erythematosus admitted to the hospital from March 2021 to March 2023.According to the random number table method,they were divided into control group and study group,45 cases in each group.The control group was treated with Hydroxychloroquine combined with Prednisone,while the study group was treated with Belimumab on the basis of that of the control group.The disease activity[systemic lupus erythematosus activity index(SLEDAI)]score,the immunological indexes[complement C3,complement C4,immunoglobulin(Ig)G,IgA,IgM]levels,the Glucocorticoid dosage,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:After the treatment,the SLEDAI scores of the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).After the treatment,the levels of complement C3 and complement C4 in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of IgG,IgA and IgM in the two groups were lower than those before the treatment,and those in the observation group were lower than those in the control group;and the differences were statistically significant(P<0.05).12 and 24 weeks after the treatment,the doses of Glucocorticoids in the two groups were lower than those in the first week of treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Belimumab combined with Hydroxychloroquine and Prednisone in the treatment of the patients with systemic lupus erythematosus can reduce the SLEDAI scores,improve the levels of immunological indexes,and reduce the dosage of Glucocorticoids.Moreover,it is superior to Hydroxychloroquine combined with Prednisone treatment.
Systemic lupus erythematosusHydroxychloroquineBelimumabPrednisoneDisease activityImmune function